Bruker Corporation recently announced the signing of the definitive agreement to purchase 100 percent of the shares of Neurescence Inc., an innovative provider of ultralight fiber-bundle Multiscopes™ for simultaneous multi-region, optical functional neuroimaging. Neurescence’s flagship product Chromatone™ moves illumination and detection hardware off the animal head. This enables simultaneous imaging and stimulation of three sub-types of neurons in up to four regions for flexible investigation of the central nervous system with single-neuron resolution in naturalistic behavior. This platform creates strong synergies with Bruker’s existing Ultima multiphoton solutions and newly acquired Inscopix head-mounted miniscopes.
Neurescence is a former participant in OBIO® Health to Business Bridge™ program (H2BB™) and OBIO® Business Development Skills Program (BDSP™)